Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting

American Heart Journal

Volumn 131, Issue 2, 1996, Pages 211-218

  Muller, David W M ^a,b   Gordon, David ^b   Topol, Eric J ^c   Levy, Robert J ^b   Golomb, Gershon ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HIRULOG; POLYMER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG DOSE; DRUG THERAPY; INTIMA; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHARMACEUTICS; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; SWINE; THROMBOGENESIS;

EID: 0030065126     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90343-9     Document Type: Article

References (42)

1. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-35.
2. Nath FC, Muller DWM, Ellis SG, Rosenschein U, Chapekis A, Quain L, Zimmerman C, Topol EJ. Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome. J Am Coll Cardiol 1993; 21:622-7.
3. Chen LB, Buchanan JM. Mitogenic activity of blood components: I. Thrombin and prothrombin. Proc Natl Acad Sci USA 1975;72:131-5.
4. Harlan JM, Thompson PJ, Ross RR, Bowen-Pope DF. Alpha-thrombin induces release of platelet-derived growth factor-like molecule(s) by cultured human endothelial cells. J Cell Biol 1986;103:1129-33.
5. Graham DJ, Alexander JJ. The effects of thrombin on bovine aortic endothelial and smooth muscle cells. J Vasc Surg 1990;11:307-13.
6. Okazaki H, Majesky MW, Harker LA, Schwartz SM. Regulation of platelet-derived growth factor ligand and receptor gene expression by alpha-thrombin in vascular smooth muscle cells. Circ Res 1992;71:1285-93.
7. Stouffer GA, Sarembock IJ, McNamara CA, Gimple LW, Owens GK. Thrombin induced mitogenesis of vascular smooth muscle cells is partially mediated by autocrine production of PDGF-AA. Am J Physiol 1993;265:C806-11.
8. McNamara CA, Sarembock IJ, Gimple LW, Fenton JWL, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993;91:94-8.
9. Thornton MA, Gruentzig AR, Hollman J, King SB, Douglas JS. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 1984;69:721-7.
10. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-9.
11. Ellis SG, Roubin GS, Wilentz J, Douglas JS, King SB. Effect of 18-24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. AM HEART J 1989;117:777-82.
12. Muller DWM, Shamir KJ, Ellis SG, Topol EJ. Peripheral vascular complications after conventional and complex coronary interventional procedures. Am J Cardiol 1992;69:63-8.
13. Popma JJ, Satler LF, Pichard AD, Kent KM, Campbell A, Chuang YC, Clark C, Merritt AJ, Bucher TA, Leon TA. Vascular complications after balloon and new device angioplasty. Circulation 1993;88:1569-78.
14. Muller DWM, Golomb G, Gordon D, Levy RJ. Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation. Coronary Artery Disease 1994;5:435-42.
15. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal thickening after balloon injury in the rat carotid model. J Clin Invest 1994;93:1243-9.
16. Okada T, Bark DH, Mayberg MR. Local anticoagulation without systemic effect using a polymer heparin delivery system. Stroke 1988; 19:1470-6.
17. Okada T, Bark DH, Mayberg MR. Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation. Neurosurgery 1989;25:892-8.
18. Edelman ER, Adams DH, Karnovsky MJ. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci USA 1990;87:3773-7.
19. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79:657-65.
20. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin, and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990;82:1476-84.
21. Jang I, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990;81:219-25.
22. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991;84:232-43.
23. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar W, Rothman M, de Bono D, Fergusou J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-9.
24. Lidon R-M, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, hirulog, in unstable angina. Circulation 1993;88:1495-501.
25. Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandra KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989;264:8692-8.
26. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095-101.
27. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsch J. Clot-bound thrombin is protected from inhibition by heparin-anti-thrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
28. Golomb G, Dixon M, Smith M, Schoen FJ, Levy RJ. Controlled release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating. J Pharm Sci 1987;76:271-6.
29. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis and the proportional response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 19:267-74.
30. Sutton JM, Ellis SG, Roubin GS, Pinkerton CA, King SB, Raizner AE, Holmes DR, Kereiakes DJ, Topol EJ. Major clinical events after coronary stenting: the Multicenter Registry of acute and elective Gianturco-Roubin stent placement. Circulation 1994;89:1126-37.
31. Lincoff AM, Topol EJ, Chapekis AT, George BS, Candela RJ, Muller DWM, Zimmerman CA, Ellis SG. Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: a matched case-control study. J Am Coll Cardiol 1993;21:866-75.
32. Ellis SG, Savage M, Fischman D, Baim DS, Leon M, Goldberg S, Hirshfeld JW, Cleman MW, Teirstein PS, Walker C, Bailey S, Buchbinder M, Topol EJ, Schatz RA. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries: initial results of a multicenter experience. Circulation 1992;86:1836-44.
33. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M-A. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
34. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovitch A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
35. Dick RJ, Popma JJ, Muller DWM, Burek KA, Topol EJ. Incremental costs associated with new percutaneous coronary devices. Am J Cardiol 1991;68:879-86.
36. Murphy JG, Schwartz RS, Edwards WD, Camrud AE, Vliestra RE, Holmes DR. Percutaneous polymeric stents in porcine coronary arteries: initial experience with polyethylene terephthalate stents. Circulation 1992;86:1596-604.
37. Holmes DR, Camrud AR, Jorgenson MA, Edwards WD, Schwartz RS. Polymeric stenting in the porcine coronary artery model: differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. J Am Coll Cardiol 1994;24:525-31.
38. Zilla P, Fasol R, Preiss P, Kadletz M, Deutsch M, Schima H, Tsangaris S, Groscurth P. Use of fibrin glue as a substrate for in vitro endothelialization of PTFE vascular grafts. Surgery 1989;105:515-22.
39. Kelly AB, Maraganore LM, Bourdon P, Hanson SR, Harker LA. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci USA 1992;89:6040-4.
40. Harmon JT, Jamieson GA. Platelet activation by alpha-thrombin is a receptor-mediated event. Ann NY Acad Sci 1986;485:387-95.
41. Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, Willerson JT. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989;84:18-27.
42. Muller DWM, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol 1992;19:418-32.